Testing NNC0487-0111 for weight loss in adults with obesity
Tests a once-weekly injection against a placebo in adults with obesity.
Plain-language title generated from the registry record
Registry title: AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Key facts
- Where
- Buenos Aires, Córdoba, Esperanza, Santa Fe, Godoy Cruz, San Nicolás, and Santa Rosa, ArgentinaSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with excess body weight who have tried to lose weight with diet before and not succeeded. Participants get a weekly injection of NNC0487-0111 or placebo.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Obesity (excess body weight).
- Earlier treatment
- Must have at least one self-reported unsuccessful diet attempt to lose weight. Must not have had GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, any other GLP-1 based treatment, or amylin analogues before screening.
- Biomarker or test result
- HbA1c must be below 6.5% (48 mmol/mol) at screening.
Main reasons for not taking part
- HbA1c of 6.5% (48 mmol/mol) or higher at screening
- History of type 1 or type 2 diabetes
- Earlier treatment with GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists or other GLP-1 based treatment
- Earlier treatment with amylin analogues
Read by machine on 12 November 2026.
Where in Argentina
- Centro Medico Dra. Laura Maffei e Investigacion Clínica ApliBuenos Aires, ArgentinaContact: Novo NordiskTaking people
- Instituto de Investigaciones Clínicas CórdobaCórdoba, ArgentinaContact: Novo NordiskTaking people
- Sanatorio EsperanzaEsperanza, Santa Fe, ArgentinaContact: Novo NordiskTaking people
- CIPADIGodoy Cruz, ArgentinaContact: Novo NordiskTaking people
- Instituto de Investigaciones Clinicas San NicolásSan Nicolás, ArgentinaContact: Novo NordiskTaking people
- Fundación CESIMSanta Rosa, ArgentinaContact: Novo NordiskTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07339423EU 2024-520440-42-00
- Record updated
- 24 September 2026
- Original description
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.Read full original descriptionShow less
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Inclusion: Male or female (sex at birth); Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study; History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records; HbA1c ≥ 6.5% (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening.